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Abstract: Coffee consumption has been related to a preventive effect against several non-transmissible
pathologies. Due to the content of this beverage in phytochemicals and minerals, it has been proposed
that its impact on health may partly depend on gut microbiota modulation. Our aim was to explore
the interaction among gut microbiota, fecal short chain fatty acids, and health-related parameters
in 147 healthy subjects classified according to coffee consumption, to deepen the association of the
role of the (poly)phenol and alkaloid content of this beverage. Food daily intake was assessed
by an annual food frequency questionnaire (FFQ). Coffee consumption was categorized into three
groups: non-coffee-consumers (0–3 mL/day), moderate consumers (3–45 mL/day) and high-coffee
consumers (45–500 mL/day). Some relevant groups of the gut microbiota were determined by
qPCR, and concentration of fecal short chain fatty acids by gas chromatography. Serum health
related biomarkers were determined by standardized methods. Interestingly, a higher level of
Bacteroides–Prevotella–Porphyromonas was observed in the high consumers of coffee, who also had
lower levels of lipoperoxidation. Two groups of coffee-derived (poly)phenol, methoxyphenols
and alkylphenols, and caffeine, among alkaloids, were directly associated with Bacteroides group
levels. Thus, regular consumption of coffee appears to be associated with changes in some intestinal
microbiota groups in which dietary (poly)phenol and caffeine may play a role.
Keywords: coffee; (poly)phenol; gut microbiota; Bacteroides
1. Introduction
Coffee is one of the most consumed non-alcoholic beverages worldwide and it may exert different
effects at a physiological level [1]. Although it has traditionally been considered as a beverage with
very low nutritional value, epidemiological evidence suggests that moderate coffee consumption
may reduce the risk of chronic diseases such as metabolic syndrome, obesity, type 2 diabetes [2],
cardiovascular diseases [3], or some types of cancer [4–6]. Coffee may impact directly on the host
gastrointestinal physiology by increasing intestinal motility and reducing intestinal transit time [7,8]. Some
of these widely described benefits of coffee have been attributed to its high content in non-nutritional
compounds such as phenolic compounds, fibers, minerals, and caffeine [9], which may also influence
host metabolic pathways related to health maintenance. From these compounds, caffeine, (poly)phenols,
and fibers are able to reach and exert some of their effects in the large intestine, being fermented by
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the gut microbiota [10]. Thus, given the pivotal role that microbiota plays on human nutrition and
health [11], it is possible that some of the beneficial effects of the coffee components may be related
with the participation of the gut microbiota in the metabolism of such compounds. Interventional
studies analyzing the impact of a moderate coffee intake during three weeks in a healthy population
have reported an increase of Bifidobacterium [9], sometimes also linked to a decrease of Clostridium
and Escherichia coli [9,12–14]. Regarding other bacterial groups, such as Bacteroides, the results in
the literature remain controversial [9,13,15,16]. Among the possible mechanisms to explain these
associations, data from in vitro studies pointed to a direct relationship between chlorogenic acids
and selective changes on the Blautia coccoides–Eubacterium rectale group [10] and between caffeine
and the abundance of the Lactobacillus species [17]. Based on previous evidences indicating that
theobromine, an alkaloid present in coffee, can enhance (poly)phenol absorption in the intestine [18],
a synergistic effect for phenolic compounds and alkaloids on the intestinal microbiota at this location
may be plausible. To date, most of the studies analyzing the impact of coffee on the composition of
the intestinal microbiota come from in vitro, animal, or intervention studies. However, to the best
of our knowledge, no observational studies are currently available analyzing the impact of regular
coffee consumption on fecal microbiota, taking into consideration the influence that the content of this
beverage in caffeine and phenolic compounds may exert on the microbiota. This information would
contribute to expand the existing knowledge about the impact of coffee on gastrointestinal physiology
and therefore, on health maintenance.
2. Subjects and Methods
The study included 147 participants, with ages ranging from 19 to 95 years and body mass index
(BMI) scores between 19.0 and 39.0 kg/m2 who were recruited in Asturias (Atlantic coast of Spain).
Volunteers were cited individually, informed about the study, and gave informed written consent before
enrolment. Inclusion criteria were the absence of diagnosed immune or digestive related pathologies as
well as non-consumption of corticoids, immunosuppressive drugs, monoclonal antibodies, antibiotics,
or immunotherapy, and not having consumed probiotics or prebiotics as dietary supplements during
the previous month.
The study was approved by the Bioethics Committee of CSIC (Consejo Superior de Investigaciones
Científicas) and the Regional Ethics Committee for Clinical Research (Servicio de Salud del Principado
de Asturias n 13/2010).
2.1. Nutritional Assessment
Participants were instructed to maintain their usual dietary pattern before the study. Regular
food intake was assessed by trained personnel in a personal interview of approximately 1 h duration,
using an annual semi-quantitative food frequency questionnaire (FFQ), previously validated [19,20].
Methodological issues about dietary assessment were published elsewhere [18]. Food consumption
was transformed into energy and macronutrients intake using the food composition tables of
CESNID (Centro de Enseñanza Superior de Nutrición Humana y Dietética) [21]. Caffeine intake was
estimated from the United States Department of Agriculture (USDA) food composition database [22].
The polyphenols content in foods was completed using the Phenol Explorer database that compiled
detailed information from over 400 foods and beverages, including coffee [23] and fiber components,
and were ascertained using the Marlett et al. food composition tables [24].
At the time of carrying out the blood extraction, height and weight were taken by standardized
protocols previously described [25] in order to calculate the BMI by the formula: weight (kg)/height (m2).
2.2. Blood Biochemical Analyses
Fasting blood samples were drawn by venipuncture and centrifuged (1000× g, 15 min). Plasma
and serum aliquots were kept at −20 ◦C until analyses. Plasma glucose, cholesterol, and triglycerides
were determined by standard methods. Serum C-reactive protein (CRP) levels were determined by
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ELISA (CRP Human Instant ELISA, Ebioscience, San Diego, CA, USA), and malondialdehyde (MDA)
by using the Byoxytech LPO-586 assay (Oxis International S.A., Paris, France) [26]. Serum leptin was
determined by using the Human Leptin ELISA Development Kit 900-K90 (PeproTech Inc., Rocky Hill,
NJ, USA) according to the manufacturer’s instructions.
2.3. Fecal Collection and Microbial Analysis
Participants were provided with a sterile container for fecal sample collection; after deposition
samples were immediately frozen at −20 ◦C and transported to the laboratory. For analyses, samples
were melted at room temperature (24 ± 2 ◦C), weighed, diluted 1/10 in sterile PBS, and homogenized
(LabBlender 400 Stomacher, Seward Medical, London, UK) for 4 min; the DNA was extracted using the
QIAamp DNA stool mini kit (Qiagen, Hilden, Germany) as described elsewhere [27]. Quantification
of different bacterial populations, covering the major bacterial groups present in the human gut,
was achieved in a 7500 Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using
SYBR Green PCR Master Mix (Applied Biosystems) [27] (Table 1). One microliter of template fecal DNA
(~5 ng) and 0.2 µM of each primer were added to the 25 µL reaction mixture. PCR cycling consisted
of an initial cycle of 95 ◦C 10 min, followed by 40 cycles of 95 ◦C 15 s, and 1 min at the appropriate
primer−pair temperature. The number of cells was determined by comparing the Ct values obtained
from a standard curve as previously described [27]. Fecal DNA extracts were analyzed and the mean
quantity per gram of fecal wet weight was calculated for each bacterial group.
Major short chain fatty acid (SCFA), acetate, propionate, and butyrate were analyzed by gas
chromatography from the supernatants of 1 mL of the homogenized feces as previously indicated [28].
A chromatograph 6890N (Agilent Technologies Inc., Palo Alto, CA, USA) connected to a mass
spectrometry detector (MS) 5973N (Agilent Technologies) and a flame ionization detector (FID) was
used for identification and quantification of SCFA, respectively, as described previously [29].
Table 1. Primers and annealing temperatures used for the quantification of intestinal microbial groups
by qPCR.
Microbial Group Primer Sequence (5′-3′) Tm. (◦C)
Akkermansia F: CAGCACGTGAAGGTGGGGACR: CCTTGCGGTTGGCTTCAGAT 60
Bacteroides-Prevotella-Porphyromonas F: GAGAGGAAGGTCCCCCACR: CGCKACTTGGCTGGTTCAG 60
Bifidobacterium F: GATTCTGGCTCAGGATGAACGCR: CTGATAGGACGCGACCCCAT 60
Clostridia cluster XIVa group F: CGGTACCTGACTAAGAAGCR: AGTTTYATTCTTGCGAACG 55
Faecalibacterium prausnitzii F: GGAGGAAGAAGGTCTTCGGR: AATTCCGCCTACCTCTGCACT 60
Lactobacillus group F: AGCAGTAGGGAATCTTCCAR: CATGGAGTTCCACTGTCCTC 60
Adapted from Reference [28].
2.4. Statistical Analyses
Statistical analysis was performed using the IBM SPSS program version 24.0 (IBM SPSS, Inc.,
Chicago, IL, USA). Goodness of fit to the normal distribution was analyzed by means of the
Kolmogorov−Smirnov test. When the distribution of variables was skewed, the natural logarithm of
each value was used in the statistical test. For descriptive purposes, mean values are presented on
untransformed variables. Differences in general and anthropometric characteristics, blood parameters,
gut microbial groups, and fecal SCFA were assessed in accordance to tertiles of coffee intake through
multivariate analyses adjusted by age, gender, BMI, and energy, based on the strong evidences linking
these factors with human microbial composition. Pearson correlation was conducted to elucidate the
interplay between caffeine and polyphenols from coffee and intestinal microbiota. The conventional
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probability value (0.05) for significance was used in the interpretation of results. Results obtained from
the sample analysis were plotted using Microsoft Excel Software version 2016 (Microsoft Corporation,
Redmon, Washington, USA). Data resulting from the Pearson correlation tests were plotted using
GraphPad Prism version 8 for Windows (GraphPad Software, San Diego, CA, USA).
3. Results
The general characteristics of the sample are described in Table 2 according to the coffee tertiles.
No statistically significant differences were found based on coffee consumption for any of the variables
evaluated, with the exception of age, which was lower in subjects with the highest consumption of
coffee (tertile 3).
Table 2. General characteristics of the study sample according to coffee consumption tertiles.
Characteristic
Coffee (mL/day)
T1 (0–3)
(n = 49)
T2 (>3–45)
(n = 49)
T3 (>45–500)
(n = 49)
Age (years) 58.8 ± 18.62 a 67.57 ± 14.77 b 47.10 ± 10.86 c
Gender (% female) 69% 71% 71%
BMI (kg/m2) 28.08 ± 4.52 a 27.32 ± 3.55 a 26.73 ± 5.16 a
Sleep duration (h/day) 6.78 ± 1.06 a 6.73 ± 1.07 a 7.00 ± 1.31 a
Energy intake (Kcal/day) 1906.93 ± 494.27 a 1776.89 ± 531.64 a 2040.23 ± 622.47 a
Coffee consumption (mL/day) 0.15 ± 0.59 a 27.53 ± 11.14 b 151.84 ± 92.10 c
Tobacco user (%) 25% 28% 25%
Depositions (nº/week) 8.89 ± 6.26 a 6.49 ± 2.68 b 7.74 ± 3.84 a,b
All values are shown as mean ± standard deviation (SD). Values in the same row showing a different subscript
present a statistically significant difference (p ≤ 0.05). Tobacco user refers people with smoking-habit at the time of
the study.
The possible existence of a dietary pattern linked to coffee consumption was explored, as shown
in Figure 1.Nutrients 2020, 12, x FOR PEER REVIEW 5 of 13 
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From the 19 items analyzed, only a moderate increase in the consumption of greens and vegetables
was found across coffee tertiles, this being higher in tertile 3. As expected, since coffee is usually
consumed with sugar, significant differences were also observed in the intake of non-alcoholic beverages
and sugar products. In spite of this, the scarce differences found do not allow for a differential dietary
pattern in the high-consumers group to be defined. When the average counts of the major gut microbial
groups were analyzed, based on coffee consumption tertiles (Table 3), the sole difference observed
was a significantly higher level of Bacteroides-Prevotella-Porphyromonas in tertile 3. Nevertheless,
no differences were detected in fecal levels of SCFA according to coffee consumption, neither in the
studied serum biomarkers, with the exception of MDA, an indirect biomarker of lipid peroxidation,
whose concentration was lower in tertile 3.
Table 3. Differences in gut microbiota composition, fecal short chain fatty acids concentration (SCFA),
and serum markers according to coffee consumption tertiles.
Coffee (mL/day)
T1 (0–3) T2 (>3–45) T3(>45–500)
Model 1. Microbial group (Log n cells/gram feces) (n, 138) *
Akkermansia 5.70 ± 0.40 a 5.76 ± 0.33 a 6.30 ± 0.36 a
Bacteroides-Prevotella-Porphyromonas 8.03 ± 0.27 a 8.74 ± 0.27 a,b 9.14 ± 0.30 b
Bifidobacterium 7.61 ± 0.26 a 7.73 ± 0.26 a 8.19 ± 0.28 a
Clostridia cluster XIVa group 7.48 ± 0.29 a 7.49 ± 0.29 a 7.50 ± 0.31 a
Lactobacillus group 6.28 ± 0.27 a 5.97 ± 0.27 a 5.97 ± 0.29 a
Faecalibacterium prausnitzii 7.10 ± 0.17 a 7.29 ± 0.17 a 7.51 ± 0.19 a
Model 2. Fecal SCFA concentration (mM) (n, 132) *
Acetic acid 36.77 ± 2.51 a 36.80 ± 2.48 a 33.99 ± 2.58 a
Propionic acid 12.55 ± 1.09 a 13.97 ± 1.08 a 12.56± 1.12 a
Butyric acid 10.17 ± 1.18 a 10.90 ± 1.17 a 10.10 ± 1.21 a
Model 3. Blood parameters *
Serum MDA (µM) (n,102) 2.51 ± 0.11 a 2.28 ± 0.07 a,b 1.89 ± 0.20 b
C reactive protein (mg/L) (n,108) 1.37 ± 0.24 a 1.27 ± 0.17 a 0.69 ± 0.46 a
Leptin (ng/mL) (n,102) 11.05 ± 1.21 a 11.15 ± 0.85 a 8.34 ± 2.34 a
LDL–HDL ratio (n,125) 2.51 ± 0.18 a 2.86 ± 0.13 a 2.85 ± 0.35 a
Triglycerides (mg/dL) (n,125) 121.70 ± 11.12 a 122.08 ± 7.80 a 103.14 ± 21.44 a
Glucose (mg/dL) (n,125) 100.12 ± 5.62 a 103.05 ± 3.94 a 103.73 ± 10.84 a
Antioxidant capacity (mM) (n,72) 0.36 ± 0.02 a 0.34 ± 0.01 a 0.34 ± 0.04 a
* Results obtained from multivariate analyses adjusted by age, gender, BMI, and energy. Values in the same
row showing different subscripts present a statistically significant difference; (p ≤ 0.05). MDA, malondialdehyde;
LDL, low density lipoprotein; HDL, high density lipoprotein.
Coffee is a dietary source of various bioactive compounds including (poly)phenols and alkaloids
(Figure 2). At the compound level, the major phenolic compounds provided by coffee were caffeoylquinic
and feruloylquinic acids among hydroxycinnamics, and guaiacol from methoxyphenols (Figure 2A).
As shown in Figure 2B, coffee was the major contributor to the intake of caffeine in the sample,
explaining more than 90% of its consumption.
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(B) the dietary caffeine sources in the sample.
Furthermore, the linear relationships between coffee derived dietary components and the
microbiota was estimated through Pearson’s correlation test and are presented graphically in
the heatmap of Figure 3. From the different phenolic compounds analyzed, those derived from
coffee have shown the highest correlation with intestinal microbial groups together with caffeine.
While metoxyphenols and alkylmethoxyphenols were correlated with the levels of the Bacteroides–
Prevotella–Porphyromonas group with a r = 0.177 and 0.182, respectively, caffeine intake was directly
associated with fecal Bacteroides levels (r = 0.200).
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Figure 3. A heatmap showing Pearson correlations among intestinal microbial groups (Log n cells/gram
feces), fecal short chain fatty acids (mM), polyphenol groups (mg/day), and alkaloids (mg/day), from
coffee and other dietary source . Columns correspond to major intestinal icrobial groups and fecal
SCFA; rows correspond t dietary polyphenols and alkaloids. Blue and red colors denote negative
and positive association, respectively. The intensity of the colors represents the degree of association
between variables. Asterisks indicate significant associations: * p ≤ 0.05; ** p ≤ 0.01.
4. Discussion
Our results represent a first step in broadening the knowledge of the association between the
regular intake of coffee and fecal microbiota in an apparently healthy human population, suggesting a
possible implication of coffee phenolic compounds and caffeine in this relationship.
The mean consumptio of coffee is highly variable in the stu y sample, ranging between 0 and
500 mL/day, in a similar way to that observed in other European countries with a Mediterranean-type
dietary pattern, such as Italy or Greece [30]. Given the absence of a reference value to establish coffee
consumption levels, tertiles have been used to categorize the sample. The defined cut-off points are
coherent from a methodological point of view, since they group non-coffee-consumers (0–3 mL/day) in
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tertile 1, moderate consumers (3–45 mL/day) in tertile 2, which could correspond to those subjects
consuming a little cup of coffee per day of the so-called Italian coffee, and the tertile 3 of high consumers.
Still, it must be taken into account that this tertile 3 has a lower mean intake of coffee than what
has been reported in other countries, such as Germany [30]; therefore, our data may not be directly
extrapolated to other countries with different trends in coffee consumption. It is also important to note
that important differences in the coffee preparation procedures exist among different consumers and
different countries. In our case, the mean coffee intake in tertile 3 is slightly lower than the range of
400–600 mL [9], associated with a protective effect against various pathologies [3,31]. Interestingly,
in some studies the long-term consumption of seven cups of coffee per day has been associated with a
reduction in the risk of metabolic syndrome, obesity, and type 2 diabetes [32,33]. However, since the
coffee cup volume could vary from 150 mL to 300 mL among the studies included in the meta-analysis
of Grosso et al. [32] indicated just before, extrapolations to our results are limited.
In some impaired health conditions, alterations in the intestinal microbiota have been described,
mainly a decrease in the abundance of Bacteroides and/or an increase in the Firmicutes/ Bacteroidetes
ratio [34–36]. In line with this, we have found higher fecal levels of the Bacteroides-Prevotella-
Porphyromonas group in the high coffee consumers, supporting previous evidences in humans and
animal models having higher fecal levels of these microorganisms in groups of better metabolic
status [34–36]. It is tempting to speculate about this potential association; however, given the descriptive
nature of this cross-sectional study, we cannot establish cause–effect relationships or directionality.
Members of the phylum Bacteroidetes have been hypothesized to reduce intracellular oxygen levels,
thus favoring the growing of anaerobic species which could promote the maintenance of intestinal
balance, and they are identified as key glycan degrading bacteria [37,38] being more able to metabolize
polyphenols than other groups such as Firmicutes. In this sense, coffee polyphenols explained a
20% of total polyphenol intake in the subjects with the highest consumption (tertile 3). Therefore,
we hypothesized that at an equivalent total intake of polyphenols, the physiological effect of these
compounds may differ among subjects depending on their dietary origin. It has been demonstrated
that coffee-derived polyphenols were able to interact with intestinal bacteria in a bidirectional way:
polyphenols may modify the gut environment [39], and/or they can be catabolized by intestinal bacteria
converting them into a large variety of compounds with greater antioxidant activity than the compound
of origin [40]. Despite some coffee-derived phenolic compounds, such as chlorogenic acid, having been
associated in in vitro studies with important antioxidant and anti-inflammatory effects [41–44], we did
not find differences in serum antioxidant capacity or in C-reactive protein, depending on the coffee
consumption levels. Several factors may explain these results. Firstly, it is possible that the amount
of coffee consumed in this sample was insufficient to observe a differential effect among tertiles, and
secondly, subjects with low coffee consumption received polyphenols through other foodstuffs, thus
ultimately achieving a similar polyphenol intake to the high coffee consumers (mean intake of 1604.4
and 1487.7 mg/day in T2 and T3 respectively, p = 0.533). Considering the high impact of phenolic
compounds on gut microbial modulation, future human intervention studies analyzing the impact of
coffee on fecal microbiota [9] should evaluate the intake of dietary and specific coffee polyphenols.
Moreover, there is evidence from animal research showing that caffeine administration counteracts
shifts in the ratio, Firmicutes/Bacteroides, resulting from a western diet [45]. Although we cannot
attribute the observed differences in fecal microbial composition to a single compound, caffeine has
been positively correlated in this work with most of the gut microbial groups analyzed. In turn,
evidences of lower MDA concentrations in high coffee consumers may be in consonance with data in the
literature describing the down-regulation effect of caffeine on lipid binding proteins and consequently
in lipogenesis [46–49].
At the time of interpreting these results, the limited sample size should be considered. Nonetheless,
we have found associations whose consistency and strength justify further research. Human experimentation
in healthy subjects is limited by the logistical problems associated with carrying out direct measurements.
Fecal SCFA accounts for only 5% to 10% of SCFA production that is not absorbed in the colon [50].
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The FFQ is one of the most valid dietary tools in order to describe subjects’ regular dietary intake.
However, to accurately quantify the coffee derived polyphenols, it would be advisable to register more
detailed information about coffee such as the variety, the amount of powder used, ground grain size,
and the final volume obtained [30]. Since we did not have individuals with daily intakes greater than
500 mL, it would be desirable in the future to be able to expand this group to deepen the association
between this beverage and intestinal microbiota and oxidative stress, and to determine whether this
would be dose dependent.
5. Conclusions
The interaction between coffee consumption, a modifiable factor, and intestinal bacteria may be
useful for the development of dietary strategies in humans focused on diverse pathologies where the
concentration of the Bacteroides group was altered.
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